Press Releases

Press Releases
Date Title and Summary View
May 10, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today announced that the Company will be presenting at the Acumen Biofin Rodman & Renshaw 4th Annual Global Healthcare Conference, being held May 14-15, 20...
May 9, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today provided an update on its topically applied Hedgehog agonist program for hair growth. Preclinical research efforts on Hedgehog agonist compounds for hair ...
May 2, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today reported its financial results for the quarter ended March 31, 2007. For the first quarter of 2007, we reported a net loss of $3,541,000, or ($0.07) per sh...
Apr 25, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, will release its first quarter 2007 financial results on Wednesday, May 2, before the market opens. The Company will also hold a conference call at 10:00 a.m. Eastern o...
Apr 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 17, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that its data was included in two presentations at the 98th Annual Meeting of the American Association for Cancer Research (AACR). At AACR, Cu...
Apr 11, 2007 CAMBRIDGE, Mass., Apr 11, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that the company will be presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference, being held April 11th and 1...
Mar 14, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 14, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that it has selected the first development candidate from its Targeted Cancer Drug Development Platform. Curis is seeking to use this platform to discove...
Feb 14, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 14, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focusing on signaling pathway drug technologies to create new medicines primarily for cancer, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2006. For the fourth quarter of 2006, ...
Feb 1, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2007--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will release its year end and fourth quarter financial results on Wednesday, February 14, 2007 before the market opens. The Company will also hold a conf...
Jan 31, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2007--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, announced today that Genentech, a collaborator, has treated the first patient in a Phase I clinical trial of a systemically administered small molecule ...
FirstPrevious ...
34
Add to Briefcase = add release to Briefcase